Accumetrics' Plavix prognostic:
This article was originally published in Clinica
Accumetrics has received US FDA clearance to market its VerifyNow P2Y12 blood test for determining a patient's response to Plavix (clopidogrel) - a drug used by almost 10 million patients in the US to prevent heart attack or stroke. According to the San Diego, California-based firm, some 5-30% of patients do not respond adequately to the drug. The easy-to-perform test, which provides results in less than 15 minutes, works by measuring the inhibiting effect of Plavix on platelets - blood cells primarily responsible for clotting. The test can also be used to assess a patient's clotting function prior to surgery. The company also markets VerifyNow tests for aspirin and GP IIb/IIIa inhibitors.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.